Poster & Publications

Circulating H3K27me3 modified nucleosomes as a biomarker to monitor anti EZH2-based treatment in advanced solid tumour patients

April 09, 2024

Share
Tweet
Share on Facebook
Share

Poster titled: Circulating H3K27me3 modified nucleosomes as a biomarker to monitor anti EZH2-based treatment in advanced solid tumour patients: translational analyses from CAIRE trial

Presented at: AACR 2024

Salani et al

Download

Poster & Publications
Physical isolation of tumour associated ctDNA fragments for novel AML liquid biopsy
Poster & Publications
Novel ctDNA technology for early cancer detection by immunoprecipitation of tumor associated ctDNA fragments and analysis by qPCR

Share
Tweet
Share on Facebook
Share

Subscribe for Volition product updates.

Or, click here for Investor Updates and press releases.

"*" indicates required fields

Receive product updates for:

Animal Health

Human Health

Name

First Name Last Name

Company Name*

Your Email Address*

CAPTCHA

Circulating H3K27me3 modified nucleosomes as a biomarker to monitor anti EZH2-based treatment in advanced solid tumour patients

Related Articles

Physical isolation of tumour associated ctDNA fragments for novel AML liquid biopsy

Novel ctDNA technology for early cancer detection by immunoprecipitation of tumor associated ctDNA fragments and analysis by qPCR

Subscribe for Volition product updates.

Or, click here for Investor Updates and press releases.

Contact